Regorafenib

Generic Name
Regorafenib
Brand Names
Stivarga
Drug Type
Small Molecule
Chemical Formula
C21H15ClF4N4O3
CAS Number
755037-03-7
Unique Ingredient Identifier
24T2A1DOYB
Background

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...

Associated Conditions
Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

First Posted Date
2016-01-26
Last Posted Date
2022-04-14
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
34
Registration Number
NCT02664077
Locations
🇺🇸

McLeod Cancer Center for Treatment and Research, Florence, South Carolina, United States

🇺🇸

Thompson Cancer Survival Center, Knoxville, Tennessee, United States

🇺🇸

First Health of the Carolinas Cancer Center, Pinehurst, North Carolina, United States

and more 48 locations

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2016-01-18
Last Posted Date
2024-11-11
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
8
Registration Number
NCT02657551
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

Phase II Study of Perindopril and Regorafenib in mCRC

First Posted Date
2016-01-11
Last Posted Date
2019-09-12
Lead Sponsor
British Columbia Cancer Agency
Target Recruit Count
12
Registration Number
NCT02651415
Locations
🇨🇦

BC Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-12-23
Last Posted Date
2023-03-27
Lead Sponsor
Grupo Espanol de Investigacion en Sarcomas
Target Recruit Count
15
Registration Number
NCT02638766
Locations
🇪🇸

Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

🇮🇹

Policlinico Universitario Campus Bio-Medico, Roma, Italy

and more 14 locations

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2015-12-02
Last Posted Date
2023-03-24
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
46
Registration Number
NCT02619435
Locations
🇮🇹

AO G. Rummo, Benevento, Italy

🇮🇹

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy

🇮🇹

Seconda Università di Napoli, Napoli, Italy

and more 1 locations

Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-11-17
Last Posted Date
2019-03-21
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
19
Registration Number
NCT02606097
Locations
🇨🇳

Chang Gung Memorial Hospital, Taoyuan, Taiwan

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-10-22
Last Posted Date
2023-09-06
Lead Sponsor
ARCAGY/ GINECO GROUP
Target Recruit Count
68
Registration Number
NCT02584465
Locations
🇫🇷

ORACLE - Centre d'Oncologie de Gentilly, Nancy, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Centre Catherine de Sienne, Nantes, France

and more 18 locations

Efficacy of Ginseng for Patients on Regorafenib

First Posted Date
2015-10-20
Last Posted Date
2024-06-26
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
10
Registration Number
NCT02581059
Locations
🇺🇸

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

🇺🇸

IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States

🇺🇸

Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath